Biocon Share News - Latest Updates, Live News & More

Latest news about Biocon

Biocon Launches Rs 4,500 Crore QIP to Provide Investor Exits and Close Listing Window for Subsidiary 1 day ago

Biocon has initiated a Qualified Institutions Placement (QIP) to raise Rs 4,500 crore, setting a floor price of Rs 340.20 per equity share. The funds will be used to provide exits to private equity investors in Biocon Biologics Ltd, redeem Optionally Convertible Debentures issued to Goldman Sachs entities, and pre-pay other financial commitments. This move will increase Biocon's stake in Biocon Biologics to 73.84%. The final issue price will be determined in consultation with Book Running Lead Managers.

Biocon Approves Qualified Institutional Placement at ₹340.20 Per Share 2 days ago

Biocon Launches ₹4,500 Crore QIP with ₹340.20/Share Floor Price 2 days ago

Biocon Secures DCGI Approval for Generic Diabetes Drug Liraglutide Jun 03, 2025

Biocon Secures Approval for Generic Liraglutide in India, Expanding Diabetes Treatment Options Jun 02, 2025

More news about Biocon

15May 25

Biocon Pharma Secures FDA Approval for Generic Rivaroxaban Tablets

Biocon Ltd.'s subsidiary, Biocon Pharma, has received FDA approval for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP. The approval covers four strengths: 2.5 mg, 10 mg, 15 mg, and 20 mg. This generic version of the anticoagulant medication positions Biocon to compete in the U.S. anticoagulant market, potentially increasing access to affordable treatments for blood clot prevention and treatment.

12May 25

Biocon Shares Dip Despite Analyst Optimism; Q4 Results Show Mixed Performance

Biocon Ltd experienced a share price decline on May 12, despite 'buy' ratings from Jefferies and Citi with price targets of ₹370 and ₹430 respectively. Q4 FY2025 results showed mixed performance: revenue grew 15.41% to ₹4,415.40 crore, EBITDA increased 42.35% to ₹1,076.60 crore, and net profit surged 466.46% to ₹459.40 crore. However, ex-gRevlimid EBITDA margin declined. The company plans an equity fund raise and aims to launch five new biosimilar assets in 12-18 months. US drug pricing policy changes could impact future performance.

12May 25

Biocon Chairperson Optimistic About Low US Pharma Tariffs

Biocon's chairperson has expressed optimism regarding expected US pharmaceutical tariffs, suggesting they will be 'fairly low'. This could lead to cost-effective operations, enhanced competitiveness, and expanded market opportunities for Biocon in the US market. However, final tariff decisions are subject to governmental policies and international trade agreements.

12May 25

Biocon Expects Boost in Profitability from New Product Launches

Biocon anticipates improved operating leverage and gross margins due to upcoming product launches. The new products are expected to generate higher incremental gross margins and lead to better resource utilization. This strategy could significantly enhance Biocon's overall profitability and strengthen its market position in the biopharmaceutical sector.

08May 25

Biocon Anticipates API Business Recovery, Expands GLP-1 Portfolio

Biocon anticipates a recovery in its Active Pharmaceutical Ingredients (API) business by fiscal year 2026. The company is also expanding its differentiated Glucagon-Like Peptide-1 (GLP-1) portfolio into new markets, focusing on treatments for type 2 diabetes and obesity. These strategic moves aim to drive growth and enhance Biocon's position in the global pharmaceutical market.

08May 25

Biocon's Q4 FY25 Profit Doubles, Beats Estimates, Declares Dividend

Biocon reported impressive Q4 FY2025 results, with consolidated net profit soaring 154% YoY to ₹344.50 crore. Revenue increased 12.8% to ₹4,417.00 crore, while EBITDA grew 17.7% to ₹1,078.20 crore. The EBITDA margin expanded to 24.40%. The company declared a final dividend of ₹0.50 per share.

05May 25

Biocon Biologics Secures Widespread US Market Access for Yesintek, Covering Over 100 Million Lives

Biocon Biologics Ltd. has secured market access agreements for Yesintek™, its biosimilar to Stelara® (ustekinumab), covering over 100 million lives in the US. Major health plans and pharmacy benefit managers, including Express Scripts, Cigna, UnitedHealthcare, CVS Health, and Optum Rx, have added Yesintek to their formularies. The biosimilar has also been chosen as the exclusive ustekinumab option by several providers. Yesintek, approved for treating Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, received FDA approval in December 2024.

26Apr 25

Biocon Biologics Secures Positive CHMP Opinions for Biosimilar Denosumab in Europe

Biocon Biologics Ltd (BBL) has received positive opinions from the European Medicines Agency's CHMP for two denosumab biosimilars, Vevzuo® and Denosumab BBL, for bone health indications. The recommendations are based on comprehensive clinical data showing comparability with the reference product. The European Commission will now review these opinions for final approval. This development marks a significant step in BBL's European expansion and could potentially increase access to affordable bone health treatments.

24Apr 25

Biocon Board Approves Rs 4,500 Crore Fundraise and Share Capital Expansion

Biocon's board has approved raising up to Rs 4,500 crore through various securities and increasing authorized share capital from Rs 625 crore to Rs 700 crore. The fundraising will use methods like QIP, rights issues, and private placements. The share capital increase involves expanding from 125 crore to 140 crore equity shares, each valued at Rs 5. Both proposals await shareholder and regulatory approvals. These moves suggest Biocon is preparing for significant expansion or investment opportunities in the biopharmaceutical sector.

23Apr 25

Biocon Unveils Ambitious ₹4,500 Crore Fundraising Plan and Share Capital Expansion

Biocon Limited's Board of Directors has approved a plan to raise up to ₹4,500 crore through various securities issuance methods, including QIP, rights issue, and preferential allotment. The company will issue securities in tranches, with options including equity shares and convertible securities. To support this, Biocon is increasing its authorized share capital from ₹625 crore to ₹700 crore. The plan requires shareholder and regulatory approvals.

21Apr 25

Biocon to Explore Diverse Fundraising Options in Upcoming Board Meeting

Biocon Limited has announced a board meeting on April 23, 2025, to consider various fundraising options including QIP, Rights Issue, FPO, and Preferential Allotment. The move aims to strengthen the company's financial position, potentially supporting future growth initiatives. Any fundraising will be subject to necessary approvals and shareholder consent, reflecting Biocon's commitment to regulatory compliance.

15Apr 25

Biocon Biologics Secures U.S. Market Entry for Eylea Biosimilar, Yesafili™

Biocon Biologics Ltd has reached a settlement with Regeneron for the commercialization of Yesafili™, an interchangeable biosimilar to Eylea®, in the United States. The agreement allows for launch in the second half of 2026 or earlier under certain conditions. Yesafili™, approved by the FDA in May 2024, is indicated for various ophthalmology conditions. This development marks Biocon's strategic entry into the U.S. ophthalmology market and positions the company as a key player in providing affordable alternatives for patients.

11Apr 25

Biocon's Subsidiary Secures FDA Approval for Cancer Drug Biosimilar, Expanding US Portfolio

Biocon Limited's subsidiary, Biocon Biologics, has received FDA approval for Jobevne, a biosimilar to the cancer drug Avastin (bevacizumab). This marks Biocon's seventh FDA-approved biosimilar in the US. The approval comes as bevacizumab sales in the US reached approximately $2.00 billion in 2023. Additionally, Biocon Pharma Limited received FDA approval for its Everolimus Tablets ANDA in multiple strengths, further diversifying the company's product portfolio in the US market.

10Apr 25

Biocon Biologics Secures FDA Approval for Cancer Drug Jobevne, Expanding US Oncology Portfolio

Biocon Biologics Ltd has received FDA approval for Jobevne™ (bevacizumab-nwgd), a biosimilar to Avastin®, for treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., expanding its oncology portfolio. Jobevne, a VEGF inhibitor, offers a potentially more affordable alternative to Avastin®, which had $2 billion in U.S. sales in 2023. The biosimilar is approved for multiple cancer types including colorectal, lung, and ovarian cancers. Biocon already markets bevacizumab in Europe and Canada as ABEVMY.

01Apr 25

Biocon to Consider Raising Funds Through Commercial Papers in Upcoming Board Meeting

Biocon Limited has announced a board meeting for April 4, 2025, to discuss and potentially approve fundraising through Commercial Papers (CPs) or other private placement methods. The meeting, in compliance with SEBI regulations, aims to explore short-term financing options and maintain financial flexibility. The company will disclose the meeting's outcomes on its official website, demonstrating commitment to transparency and regulatory compliance.

07Mar 25

Biocon Biologics Reports Positive Phase 3 Results for Psoriasis Drug YESINTEK™

Biocon Biologics Ltd., a subsidiary of Biocon Limited, announced successful Phase 3 study results for YESINTEK™, a biosimilar to ustekinumab (Stelara®), for treating chronic plaque psoriasis. The study demonstrated equivalent efficacy, similar safety profiles, and comparable pharmacokinetic and immunogenicity profiles between YESINTEK™ and Stelara®. YESINTEK™ received FDA approval in December 2024 for multiple indications including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This positions Biocon Biologics to potentially capture a significant share of the global ustekinumab market.

06Mar 25

Biocon Biologics Partners with Civica to Boost Insulin Aspart Availability in the US

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has entered a strategic agreement with Civica, Inc. to supply insulin aspart drug substance for the US market. Civica will produce the insulin aspart drug product at its Virginia facility. This collaboration aims to increase availability and affordability of this rapid-acting insulin analog for American diabetes patients. The partnership addresses a critical need, as diabetes affects 38.4 million people in the US, with many struggling to afford insulin. The agreement is separate from Biocon Biologics' own Insulin Aspart Drug Product currently under FDA review.

05Mar 25

Biocon Ltd. Sees Major Block Trade Amid FDA Approvals for Key Drugs

Biocon Ltd. experienced a significant block trade of 603,674 shares at Rs. 324.75 per share, totaling Rs. 19.60 Crores on the NSE. Simultaneously, its subsidiary, Biocon Pharma Limited, received FDA approvals for Lenalidomide Capsules, Dasatinib Tablets, and tentative approval for Rivaroxaban Tablets. These approvals expand Biocon's portfolio in cancer and blood disorder treatments, potentially boosting its presence in the U.S. pharmaceutical market.

05Mar 25

Biocon Subsidiary Secures FDA Approvals for Key Cancer Drugs, Boosting Oncology Portfolio

Biocon's subsidiary, Biocon Pharma Limited, has received final FDA approvals for Lenalidomide Capsules and Dasatinib Tablets, both used in cancer treatment. The company also obtained tentative approval for Rivaroxaban Tablets, an anticoagulant. These approvals significantly expand Biocon's complex generics portfolio in the U.S. market, particularly strengthening its presence in oncology.

28Feb 25

Biocon Expands UK Presence with Launch of Liraglutide for Diabetes and Obesity

Biocon Limited has launched its GLP-1 drug Liraglutide in the UK market under two brand names: Liraglutide Biocon for diabetes and Biolide for chronic weight management. This follows MHRA approval, making Biocon the first generics company to obtain approval for gLiraglutide in a major regulated market. The company plans to expand to other European markets, the US, and emerging markets, viewing GLP-1 therapies as a significant growth driver.

24Feb 25

Biocon Biologics Launches YESINTEK™, Biosimilar to Stelara®, in US Market

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, has launched YESINTEK™ (ustekinumab-kfce), a biosimilar to Stelara®, in the United States. FDA-approved in December 2024, YESINTEK™ is indicated for treating Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Available in multiple formulations, the product aims to increase patient access to cost-effective treatments for chronic autoimmune diseases. Biocon ensures commercial payor coverage and offers a patient assistance program. This launch marks Biocon's first product introduction in the US as a fully integrated global biosimilars organization.